Product Information

IRBESARTAN 300 MG TABLET is a generic product labeled by Unichem Pharmaceuticals (USA) Inc., priced at $0.1647 per EA under NDC 29300021413. Its NADAC has been published 129 times since May 29, 2024.

FDA first approved this application on Dec 7, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

IRBESARTAN 300 MG TABLET

Irbesartan
$0.1647per EA

Strength

300 mg/1

NDC

29300021413

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

IRBESARTAN

Approval Type

Generic (ANDA)

FDA Application

ANDA203020

FDA Approved

12/7/2015

TE Code

AB

On Market Since

12/7/2015

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker

Price Statistics

The NADAC for IRBESARTAN 300 MG TABLET has been published 129 times since May 29, 2024, and over the history we have for it it has risen 11.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1647 per EA
All-time high$0.2077 (Sep 11, 2024)
All-time low$0.1461 (Feb 18, 2026)
52-week high$0.1647
52-week low$0.1461
Median price$0.1561
Average price$0.1660
Largest weekly change+33.1% (Aug 21, 2024)
Weeks tracked129
Tracking sinceMay 29, 2024

Price History

1W

0.0%

1M

+1.5%

3M

+5.9%

6M

+7.8%

1Y

+7.2%

3Y

N/A

5Y

N/A

All

+11.2%

Generic Alternatives

The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of IRBESARTAN 300 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for IRBESARTAN 300 MG TABLET, manufactured by Unichem Pharmaceuticals (USA) Inc., is $0.1647 per EA (NDC 29300021413), effective Nov 11, 2026.

How has the price of IRBESARTAN 300 MG TABLET changed over time?

Over the history we have for it, the NADAC for IRBESARTAN 300 MG TABLET has risen 11.2%. It has been tracked across 129 weekly CMS publications since May 29, 2024.

What are the highest and lowest recorded NADAC prices for IRBESARTAN 300 MG TABLET?

Since May 29, 2024, the NADAC for IRBESARTAN 300 MG TABLET has ranged from a low of $0.1461 (Feb 18, 2026) to a high of $0.2077 (Sep 11, 2024), with a median of $0.1561 per EA.

Are there cheaper alternatives to IRBESARTAN 300 MG TABLET?

Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IRBESARTAN 300 MG TABLET, is $0.1555 per EA — about 6% below IRBESARTAN 300 MG TABLET.

Who manufactures IRBESARTAN 300 MG TABLET?

IRBESARTAN 300 MG TABLET (NDC 29300021413) is labeled by Unichem Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.